Morning Briefing
Summaries of health policy coverage from major news organizations
Costly Drugs Known as Biologics Prompt Exclusivity Debate
"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
